Boston Family Office LLC Has $22.85 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Boston Family Office LLC boosted its stake in Stryker Co. (NYSE:SYK) by 0.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,259 shares of the medical technology company’s stock after purchasing an additional 157 shares during the quarter. Stryker comprises about 1.5% of Boston Family Office LLC’s holdings, making the stock its 20th biggest position. Boston Family Office LLC’s holdings in Stryker were worth $22,853,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in SYK. Mount Yale Investment Advisors LLC acquired a new position in shares of Stryker during the first quarter valued at about $305,000. Ascent Group LLC grew its holdings in shares of Stryker by 1.9% during the first quarter. Ascent Group LLC now owns 3,631 shares of the medical technology company’s stock valued at $1,299,000 after buying an additional 69 shares during the last quarter. Bayesian Capital Management LP acquired a new position in shares of Stryker during the first quarter valued at about $895,000. Kennedy Capital Management LLC acquired a new position in shares of Stryker during the first quarter valued at about $957,000. Finally, High Falls Advisors Inc acquired a new position in shares of Stryker during the first quarter valued at about $205,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on SYK shares. Needham & Company LLC raised their price target on shares of Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group raised their price target on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wolfe Research started coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price target on the stock. BTIG Research raised their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, UBS Group raised their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $393.65.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This trade represents a 42.25 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,381 shares of company stock valued at $24,825,275. Company insiders own 5.50% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $384.85 on Monday. The stock has a market capitalization of $146.71 billion, a P/E ratio of 41.25, a PEG ratio of 2.90 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm’s 50 day moving average is $366.20 and its 200 day moving average is $349.63. Stryker Co. has a 12 month low of $285.79 and a 12 month high of $398.20.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 EPS. On average, sell-side analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.